John C. Reed - 01 May 2024 Form 4/A - Amendment Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Innovative Medicine, R&D
Signature
/s/ Laura McFalls, as attorney-in-fact for John C. Reed
Issuer symbol
JNJ
Transactions as of
01 May 2024
Net transactions value
-$1,588,177
Form type
4/A - Amendment
Filing time
31 Oct 2024, 17:57:46 UTC
Date Of Original Report
03 May 2024
Previous filing
20 Feb 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +25,255 +8253% $0.000000 25,561 01 May 2024 Direct F1
transaction JNJ Common Stock Tax liability $1,588,177 -10,984 -43% $144.59 14,577 01 May 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -25,255 -33% $0.000000 50,510 01 May 2024 Common Stock 25,255 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Share Units awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The Restricted Share Units converted into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Restricted Share Units.

Remarks:

This Form 4 is being amended to correct Table I and Table II above, as follows: (i) to correct and restate the total number of shares transacted; and (ii) to correct and restate the number of securities beneficially owned following the reported transaction as of May 1, 2024.